Major histocompatibility complex - T Cell Recognition and Functional Roles of the MHC

Functional Roles of the Major Histocompatibility Complex Introduction The Major Histocompatibility Complex (MHC) serves as the immune system's "ID card" for displaying cellular peptides. These molecules have several critical functions: they present antigens to activate immune responses, influence susceptibility to autoimmune disease, enable recognition of foreign tissue, and determine transplant compatibility. At the heart of all these functions is the ability of MHC molecules to bind peptide fragments and display them at the cell surface for inspection by T lymphocytes. Antigen Presentation: The Core Function The fundamental role of MHC molecules is to bind peptide fragments and present them to T cell receptors. This interaction doesn't occur in isolation—MHC-peptide complexes work together with co-receptors: CD4 on helper T cells or CD8 on cytotoxic T cells. These co-receptors bind to different regions of the MHC molecule, helping stabilize the interaction. Think of the MHC-peptide complex as a molecular "calling card" that announces what's happening inside or on a cell. When a T cell's receptor recognizes a compatible MHC-peptide combination, it receives a survival signal that determines whether that T cell becomes activated. This system is remarkably specific—not just any peptide will trigger activation, and not just any T cell will respond. This selectivity is crucial because the immune system must distinguish between the body's own harmless proteins and genuinely dangerous antigens. Tissue Allorecognition and Transplant Compatibility One of the most clinically important properties of MHC molecules is that T lymphocytes can recognize MHC molecules from another individual. When T cells encounter peptide-MHC complexes from a genetically different person (called allogeneic tissue), they may activate against that foreign tissue. This recognition is actually indirect—T cells aren't directly "seeing" that the MHC is foreign; rather, they're responding to how the foreign MHC presents peptides, which looks different from what the T cell was trained to expect during development. This has major implications for transplant compatibility: when a donor organ is transplanted into a recipient, T lymphocytes examine the MHC molecules on the donor cells. If the donor's MHC alleles differ from the recipient's, the transplant is recognized as foreign and attacked. The severity of this rejection can be reduced by matching MHC alleles between donor and recipient as closely as possible. This is why tissue typing for MHC compatibility is a critical step before transplantation—the more closely the donor and recipient MHC molecules match, the lower the risk of rejection. <extrainfo> Autoimmune Regulation Certain MHC alleles are strongly associated with increased risk of autoimmune diseases. The classic example is the connection between the HLA-B27 allele and ankylosing spondylitis, a chronic inflammatory disease affecting the spine. Individuals carrying HLA-B27 have a dramatically elevated risk of developing this condition compared to those without this allele. The mechanism linking specific MHC alleles to autoimmunity isn't fully understood, but it likely involves how these alleles present self-peptides. Some MHC variants may present autoantigens in ways that break immune tolerance or may have structural similarities to pathogenic peptides from bacteria or viruses, leading to cross-reactive immune attacks. </extrainfo> T Lymphocyte Recognition Restrictions The MHC Restriction Problem A fundamental principle in immunology is that T lymphocytes only recognize peptides when they're presented within an MHC molecule. A free peptide floating in the bloodstream or sitting on a surface by itself won't activate a T cell—it must be bound to that cell's MHC. This property is called MHC restriction, and it's enforced during T cell development in the thymus. Positive Selection: Building MHC Specificity During T cell development, something remarkable happens: developing T lymphocytes are screened to ensure they can recognize self-MHC molecules. This process, called positive selection, occurs in the thymus where immature T cells interact with thymic epithelial cells. Here's how it works: thymic epithelial cells present self-peptides on both MHC Class I and MHC Class II molecules. As developing T cells encounter these complexes, only those T cells whose receptors can recognize self-MHC molecules receive a "survival signal." T cells that cannot bind to the MHC molecules present in the thymus fail to receive this signal and die through apoptosis—they're eliminated because they'll never be able to interact with an MHC molecule in the body. This seems counterintuitive: why would the immune system select T cells based on their ability to recognize self-MHC? The answer lies in the next principle. Dual Specificity: Self-MHC Recognition Plus Non-Self Peptide The key to understanding T cell specificity is recognizing that mature T lymphocytes have dual specificity. They recognize self-MHC molecules (which they learned during positive selection in the thymus), but they require a non-self peptide to become activated. This is the elegant solution to a problem: if T cells only recognized specific peptides without the MHC requirement, they'd be activated by peptides anywhere in the body. But because they require both self-MHC and a foreign peptide, T cells only respond when they encounter abnormal antigens (viruses, tumor proteins, etc.) being presented on normal self-MHC—exactly the situation the immune system should respond to. Think of it like a lock-and-key system with two requirements: The T cell recognizes the shape of the MHC molecule (the lock from thymic selection) The T cell also checks what peptide is bound in that MHC (the key) Only when both match does the T cell become activated. T Cell Receptor Specificity: Linear Peptide Epitopes The T cell receptor (TCR) recognizes only linear peptide epitopes—these are amino acid sequences presented as a continuous chain within the MHC binding groove. This is fundamentally different from antibodies, which can recognize 3D structures on intact proteins. The TCR's view is limited to the peptide fragment that fits in the MHC groove, presented in a linear fashion. This specificity for linear sequences in the MHC binding groove explains why: Antigen processing is essential: Raw proteins must be broken down into peptide fragments before they can activate T cells MHC-peptide orientation matters: How the peptide sits in the groove affects whether a TCR can bind it Peptide length varies by MHC class: MHC Class I typically binds 8-10 amino acid peptides, while MHC Class II binds longer peptides (13-17 amino acids), because their binding grooves have different structures This restriction to linear epitopes in MHC grooves is what creates MHC restriction at the molecular level—it's literally a physical constraint of the binding groove size and shape.